-
2023-509761-21-00
5
2024-07-08
Metastatic colorectal cancer
-
2022-500013-32-01
5
2024-07-05
Adrenocortical carcinoma
-
2023-508204-38-00
5
2024-07-02
Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
-
2023-508100-38-00
5
2024-06-24
Advanced Biliary Cancer (ABC)
-
2023-503886-44-00
5
2024-06-10
Patients with a histological diagnosis of p53abn HREC, treated with cu
-
2023-505214-23-00
5
2024-06-07
colon carcinoma
-
2023-505436-35-00
5
2024-06-03
Untreated FLIPI 2-5 Follicular Lymphoma
-
2023-503631-18-01
5
2024-05-20
Nervous system diseases
-
2023-505660-11-00
5
2024-04-24
Cholangiocarcinoma (LTT, 26.0)
-
2023-506753-38-00
4
2024-04-16
metastatic gastric adenocarcinoma
-
2023-505871-63-00
5
2024-04-08
ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 in
-
2023-508531-30-00
4
2024-03-25
grade 1 glioma/mixed glio-neuronal tumors or pleomorphic xanthoastrocy
-
2023-504863-17-00
5
2024-02-21
1. Lupus Erythematosus, Cutaneous, Subacute
2. Chronic Cutaneous Lupus
-
2023-503708-10-00
5
2024-02-20
Locally advanced or metastatic breast cancer
-
2023-505889-29-01
4
2024-02-01
Patients with unresectable locally advanced or metastatic pancreatic c
-
2022-502980-39-00
5
2024-01-25
Estrogen receptor (ER)-positive, HER2-negative advanced breast cancer
-
2023-506102-39-00
4
2023-12-18
metastatic gastric cancer
-
2023-504555-27-00
5
2023-11-28
Myelodysplastic syndrome (MDS)
-
2022-502019-12-00
5
2023-09-14
acute myeloid leukemia
-
2022-501810-77-00
5
2023-09-01
Relapsed or Refractory Marginal Zone Lymphoma
-
2022-500974-33-00
5
2023-08-12
acute venous thromboembolism event
-
2022-500587-35-01
5
2023-07-06
Stroke
-
2024-513811-29-00
5
2023-07-03
Cardiogenic Shock
-
2024-512999-35-00
4
2023-06-23
Patients with HER 2 negative locally advanced, recurrent or metastatic